JPRN-UMIN000022652已完成未知
Impact of Apixaban on clinical outcome of the patients with Large Vessel Occlusion or stenosis - ALVO trial
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 713
研究概览
简要总结
The cumulative incidence of primary outcome was similar between the two groups. The crude HR of the Early group was 1.19 and the adjusted HR was 1.32 within 365 days.
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Patients who are considered to be ineligible for the study participation by the investigator. 2. Patients who are pregnant or potentially pregnant. 3. Patients who have a history of hypersensitivity to apixaban 4. Patients with hepatic disease having coagulation disorder and clinically important bleeding risk 5. Patients with renal failure (creatinine clearance<15 mL/min) 6. Patients with Active pathological bleeding including intracranial bleeding of any type
研究者
相似试验
已完成
不适用
Safety and Effectiveness of Apixaban Compared to Warfarin in Secondary Prevention in Patients With Atrial FibrillationNon-valvular Atrial FibrillationNCT05321810Pfizer193,565
已完成
不适用
Impact of Apixaban on Clinical Outcome of the Patients With Large Vessel Occlusion or Stenosis TrialIschemic StrokeNCT02818868Hyogo Medical University700
已完成
4 期
Safety and Effectiveness Trial of Apixaban Use in Association with Dual Antiplatelet Therapy in Atrial Fibrillation Patients Undergoing Percutaneous Coronary InterventioPatients with atrial fibrillation undergoing percutaneous coronary interventionJPRN-UMIN000015923Cardiovascular Division, Faculty of Medicine, University of Tsukuba210
尚未招募
不适用
Comparative bioequivalence study of the Apixaban 5-mg Tablets manufactured by Darman Yab Darou Company-.IRCT20130313012810N10Darman Yab Darou Pharmaceutical Company24
招募中
3 期
Comparison of the preventive effects of Apixaban and Enoxaparin on the postoperative vascular thromboembolismIRCT20230419057967N1Bagheiat-allah University of Medical Sciences160